Cowen & Co. analyst Ritu Baral downgrades Aptinyx (NASDAQ:APTX) from Outperform to Market Perform.
Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia Involving $485M In Potential Earnout
Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that the company has